The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index; 53 of the 68 sources its claims cite were checked for support.
An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy
Open accessAbstract
Background: Over half of colorectal cancers (CRCs) are hard-wired to RAS/RAF/MEK/ERK pathway oncogenic signaling. However, the promise of targeted therapeutic inhibitors, has been tempered by disappointing clinical activity, likely due to complex resistance mechanisms that are not well understood. This study aims to investigate MEK inhibitor-associated resistance signaling and identify subpopulation(s) of CRC patients who may be sensitive to biomarker-driven drug combination(s). Methods: We classified 2250 primary and metastatic human CRC tumors by consensus molecular subtypes (CMS). For each tumor, we generated multiple gene expression signature scores measuring MEK pathway activation, MEKi “bypass” resistance, SRC activation, dasatinib sensitivity, EMT, PC1, Hu-Lgr5-ISC, Hu-EphB2-ISC, Hu-Late TA, Hu-Proliferation, and WNT activity. We carried out correlation, survival and other bioinformatic analyses. Validation analyses were performed in two independent publicly available CRC tumor datasets ( n = 585 and n = 677) and a CRC cell line dataset ( n = 154). Results: Here we report a central role of SRC in mediating “bypass”-resistance to MEK inhibition (MEKi), primarily in cancer stem cells (CSCs). Our integrated and comprehensive gene expression signature analyses in 2250 CRC tumors reveal that MEKi-resistance is strikingly-correlated with SRC activation (Spearman P < 10 –320 ), which is similarly associated with EMT (epithelial to mesenchymal transition), regional metastasis and disease recurrence with poor prognosis. Deeper analysis shows that both MEKi-resistance and SRC activation are preferentially associated with a mesenchymal CSC phenotype. This association is validated in additional independent CRC tumor and cell lines datasets. The CMS classification analysis demonstrates the strikingly-distinct associations of CMS1-4 subtypes with the MEKi-resistance and SRC activation. Importantly, MEKi + SRCi sensitivities are predicted to occur predominantly in the KRAS mutant, mesenchymal CSC-like CMS4 CRCs. Conclusions: Large human tumor gene expression datasets representing CRC heterogeneity can provide deep biological insights heretofore not possible with cell line models, suggesting novel repurposed drug combinations. We identified SRC as a common targetable node–-an Achilles’ heel–-in MEKi-targeted therapy-associated resistance in mesenchymal stem-like CRCs, which may help development of a biomarker-driven drug combination (MEKi + SRCi) to treat problematic subpopulations of CRC.
Overview
CoChat Summary
TL;DR
In large CRC gene expression datasets, MEK inhibitor bypass-resistance was strongly correlated with SRC activation, EMT, mesenchymal stem-like phenotype, and CMS4 subtype. The authors propose combined MEK + SRC inhibition as a biomarker-driven strategy for KRAS/NRAS-mutant CMS4 colorectal cancers.
Key findings
- In 2250 Moffitt CRCs, the 13-gene MEKi “bypass”-resistance score was strongly correlated with SRC activation and 5-gene dasatinib sensitivity scores (both Spearman P < 10–320), but not with the 18-gene MEK activation score.
- SRC activation correlated with EMT and PC1 signature scores (both P < 10–320) and was associated with metastasis, primary tumor stage I–IV progression, disease recurrence, and poor overall survival.
- MEKi resistance and SRC activation were preferentially associated with a mesenchymal CSC-like phenotype and CMS4; CMS4 tumors had the highest 13-gene MEKi-resistance and SRC activation scores, while CMS1 had the second highest.
- MEKi + SRCi sensitivity was predicted predominantly in KRAS/NRAS-mutant CMS4 and BRAF V600E CMS1 tumors; validation included Marisa n = 585, TCGA n = 677, and Medico n = 154 cell lines, with HCT116 (CMS4, KRAS G13D) and LIM2405 (CMS1, BRAF V600E) sensitive in vitro.
Methods
- Integrative gene expression signature analysis in the Moffitt CRC dataset (n = 2250; 1485 primary, 764 metastatic), with validation in Marisa (n = 585), TCGA (n = 677), and Medico CRC cell lines (n = 154); CMS classification used CMScaller.
- Signature scores measured MEK pathway activation, MEKi bypass resistance, SRC activation, dasatinib sensitivity, EMT, PC1, stemness, WNT activity, and other programs; analyses included Spearman correlation, Kaplan–Meier survival, Mann–Whitney, Welch’s t test, and chi-square trend tests.
Limitations
- Stated by the authors: the study is retrospective and primarily in silico bioinformatic; signature scores are surrogates for MEKi or SRCi sensitivity because human tumor data from CRC patients treated with MEKi or SRCi are scarce; MEKi + SRCi has never been tested in CRC patients; cell line data are limited, and more extensive CRC cell line and PDX studies are needed.
- Evident from the text: the findings are correlational and hypothesis-generating, with no prospective clinical validation, and the CMS/signature scores may not directly measure drug response.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
32 Valid · 1 Not valid · 5 Not checked · 72 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“We recently showed that PTPRS CRISPR-knock out sensitized CRC cells to the inhibitors of ERK in association with decreased SRC activity as measured by P-SRC Y419 [35].”
§ An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy > Results > Striking correlation of MEKi resistance with SRC activation in 2250 CRCs
What the sources say
- Supportedcites [35] Davis TB, Yang M, Wang H, Lee C, Yeatman TJ, Pledger WJ. PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC. Oncotarget. 2019;10(63):6768–80. source
The Introduction identifies the HCT116 colorectal cancer cells as a CRISPR-generated PTPRS knockout and says they were more sensitive to MEK/ERK inhibitors than parental cells. The Results (Figure 5 and “The role of SRC in resistance to MEK and ERK inhibition”) report decreased SRC activity after ERK inhibition in the knockout cells, measured by SRC-Y419 phosphorylation. No page numbers are provided in our copy. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“supporting the notion that some KRAS-mutated CRC tumors are decoupled from RAS/MEK pathway activation [32]”
§ An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy > Results > Analysis of MEK activation vs. MEKi resistance signature scores in 468 human CRCs
What the sources say
- Partly supportedcites [32] Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, et al. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Med Genomics. 2010;3:26. sourceExperimental — accuracy not yet measured
In Results and Discussion (‘Baseline level of RAS pathway signature correlates with drug sensitivity’), two KRAS-mutated lung cancer cell lines had low RAS signature scores and resisted MEK inhibition. The metastatic CRC section relates signature scores to cetuximab response but does not establish that some KRAS-mutated CRC tumors lack RAS/MEK pathway activation. The claim extends a finding from lung cell lines to CRC tumors. (LLM, conf=0.86)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Thus, AR can rapidly induce drug resistance to targeted therapy in tumors that are natively “sensitive”.”
§ An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy > Background
What the sources say
- Partly supportedcites [8] Yaeger R, Yao Z, Hyman DM, Hechtman JF, Vakiani E, Zhao H, et al. Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer Res. 2017;77(23):6513–23. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) links adaptive resistance to RAF inhibitors in colorectal cancer with rapid acquired resistance when RAS expression is high. The claim omits that condition and generalizes the finding to targeted therapy and tumors more broadly. (LLM, conf=0.86)
- Partly supportedcites [9] Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100–3. sourceExperimental — accuracy not yet measured
In the section “feedback activation of EGFR” (p. 2), the paper reports that BRAF inhibition rapidly activates EGFR, allowing continued proliferation despite treatment. But it investigates intrinsically resistant colorectal cancers; its experiment in normally sensitive melanoma cells induced resistance by introducing EGFR, rather than showing adaptive resistance arising in natively sensitive tumors. (LLM, conf=0.86)
- Partly supportedcites [10] Corcoran RB, Andre T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, et al. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF(V600E)-Mutant Colorectal Cancer. Cancer Discov. 2018;8(4):428–43. sourceExperimental — accuracy not yet measured
The Introduction describes adaptive feedback that restores MAPK signaling after initial suppression by a BRAF inhibitor, and the Discussion links MAPK reactivation to resistance in BRAF V600E colorectal cancer (page numbers unavailable). The claim extends this finding to natively sensitive tumors generally, whereas the paper emphasizes that these colorectal tumors respond poorly to BRAF inhibitor monotherapy. (LLM, conf=0.84)
- Partly supportedcites [11] Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012;2(3):227–35. sourceExperimental — accuracy not yet measured
The Results report that vemurafenib initially suppressed MAPK signaling in BRAF-mutant colorectal cancer cells, but signaling rebounded within hours; the Discussion links this reactivation to reduced drug sensitivity. The paper describes these cancers as relatively insensitive to vemurafenib from the outset, not as tumors that were natively drug-sensitive and then developed resistance. (LLM, conf=0.87)
- Partly supportedcites [12] Chen G, Gao C, Gao X, Zhang DH, Kuan SF, Burns TF, et al. Wnt/beta-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer. Mol Cancer Ther. 2018;17(4):806–13. sourceExperimental — accuracy not yet measured
The Abstract and Introduction describe adaptive signaling that contributes to resistance to BRAF inhibition in colorectal cancer. But they say BRAF inhibitor monotherapy is ineffective in BRAF-mutant colorectal cancer, rather than studying tumors natively sensitive to it. The cited passages also do not establish how rapidly resistance develops. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“supporting the notion that EMT is arguably the dominant program in human CRC [25]”
§ An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy > Results > Strong correlation of SRC activation with EMT, regional metastasis and disease recurrence
What the sources say
- Supportedcites [25] Loboda A, Nebozhyn MV, Watters JW, Buser CA, Shaw PM, Huang PS, et al. EMT is the dominant program in human colon cancer. BMC Med Genomics. 2011;4:9. source
The Abstract Results identify the most dominant pattern of intrinsic gene expression in colon cancer (PC1) and report that it is tightly correlated with the EMT signature. This supports the citing sentence’s qualified characterization of EMT as arguably the dominant program in human CRC. (LLM, conf=0.93)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“It is noteworthy that the 13-gene signature was developed from cell lines treated with the MEKi for a 72 h period [6] during which AR could be induced [11].”
§ An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy > Results > Analysis of MEK activation vs. MEKi resistance signature scores in 468 human CRCs
What the sources say
- Partly supportedcites [6] Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D, et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 2010;70(6):2264–73. sourceExperimental — accuracy not yet measured
The Results (Generation of novel candidate multivariate markers) report that the authors identified a 13-gene compensatory-resistance signature. But Materials and Methods (Cell culture and cell viability assays) describes 72 hours as the period used to measure drug effects on cell growth, not as the treatment period from which the signature was developed; it describes a separate drug-treated panel exposed for 8 hours. The adaptive-resistance clause is attached to a different citation and is not assessed here. Page numbers are unavailable in our copy. (LLM, conf=0.90)
- Partly supportedcites [11] Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012;2(3):227–35. sourceExperimental — accuracy not yet measured
Citation [11] is attached to the claim that adaptive resistance could arise during the 72-hour treatment period, not to the development of the 13-gene signature. The Results and Discussion (pages unavailable) report MAPK reactivation as early as 3–6 hours after treatment with the RAF inhibitor vemurafenib. They do not establish that this occurred during MEK-inhibitor treatment; the Results instead say a MEK inhibitor blocked the observed rebound. (LLM, conf=0.83)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
64 more claims · 11 with their cited sources checked
Create a free account to see all 110 claims and every source verdict.
- Probably not a substantial claim. 17
- It may state two separate claims as one. 30
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“From gene expression signatures studies, KRAS-mutated CMS4 colorectal cancer was further predicted to respond to combined MEK and SRC inhibition (69).”
From Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine (2024) · cites this paper as [69]
In the citing paper
“| Combined MEK and SRC | | Gene expression signature of sensitivity | (69) |”
From Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine (2024) · cites this paper as [69]
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 3×
“with the mesenchymal CSC-like CMS4 subtype Heterogenous CRC has been recently classified into four consensus molecular subtypes (CMS1-4) with distinguishing features: CMS1 (MSI, immune), hypermutated, microsatellite unstable and strong immune activation; CMS2 (canonical), epithelial, marked WNT and MYC signaling activ…”
BackgroundNieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
Batlle, E., & Clevers, H. (2017) · Nature Medicine · doi:10.1038/nm.4409 · Cited by 2,769 · cited 1×
“Cancer stem cells (CSCs) are thought to be resistant to targeted therapies and responsible for metastasis, disease recurrence and poor outcomes [42, 45].”
BackgroundEMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 5×
“Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.”
BackgroundInfluentialUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051 · cited 3×
“This suggested that, in contrast to that observed with BRAFi treatments [9, 11], MEKi may mediate AR by a mechanism independent of EGFR.”
BackgroundResultToward a Shared Vision for Cancer Genomic Data
Grossman, R. L., Heath, A. P., Ferretti, V., Varmus, H. E., Lowy, D. R., Kibbe, W. A., & Staudt, L. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1607591 · Cited by 1,680 · cited 2×
“by two independent CRC tumor datasets We validated the findings from > 2000 Moffitt CRC tumors using two independent, publicly-available CRC human datasets (Marisa 585 CRCs [23] and TCGA 677 CRCs [47], see METHODS).”
MethodHyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Marisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001453 · Cited by 1,507 · cited 4×
“by two independent CRC tumor datasets We validated the findings from > 2000 Moffitt CRC tumors using two independent, publicly-available CRC human datasets (Marisa 585 CRCs [23] and TCGA 677 CRCs [47], see METHODS).”
MethodInfluential
Cited by
Soundararajan, R., Maurin, M. M., Rodriguez-Silva, J. A., Upadhyay, G., Alden, A. J., Gowda, S. G. B., Schell, M. J., Yang, M., Levine, N. J., Gowda, D., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-332535 · Cited by 55
Self-citationMouillet-Richard, S., Cazelles, A., Sroussi, M., Gallois, C., Taieb, J., & Laurent-Puig, P. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3964 · Cited by 43
“From gene expression signatures studies, KRAS -mutated CMS4colorectal cancer was further predicted to respond to combined MEK and SRC inhibition (69).”
BackgroundFan, X., Gong, M., Yu, H., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03087-5 · Cited by 26
“Src is a nonreceptor cytoplasmic kinase that mediates formation of focal adhesions and arrangement of actin filaments for cell extension, and Src activation contributes to epithelial-mesenchymal transformation, a key event in tumor stem cell development [43, 44].”
BackgroundThe potent role of Src kinase-regulating glucose metabolism in cancer
Shao, W., Liu, L., Zheng, F., Ma, Y., & Zhang, J. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115333 · Cited by 15
Anti-Cancer and Pro-Immune Effects of Lauric Acid on Colorectal Cancer Cells
Mori, S., Fujiwara‐Tani, R., Ogata, R., Ohmori, H., Fujii, K., Luo, Y., Sasaki, T., Nishiguchi, Y., BHAWAL, U. K., Kishi, S., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051953 · Cited by 15
“For example, mutations in pathways such as RAS/RAF/mitogen-activated protein kinase complicate the efficacy of specific targeted therapies, leading to treatment resistance and limited treatment options [10,11].”
Metadata
- Authors
- Yang, M., Davis, T. B., Pflieger, L., Nebozhyn, M. V., Loboda, A., Wang, H., Schell, M. J., Thota, R., Pledger, W. J., & Yeatman, T. J.
- Affiliations
- University of South Florida (US)
- Intermountain Healthcare (US)
- Moffitt Cancer Center (US)
- University of Utah (US)
- Corresponding author
- Yeatman, Timothy J.
- ORCID
- Venue
- BMC Cancer
- Published
- 2022-03-10
- Volume
- 22
- Issue
- 1
- Pages
- 256-256
- ISSN
- 1471-2407 (ISSN-L)
- PMC
- PMC8908604
- OpenAlex
- W4220962445
- Semantic Scholar
- ab7c805285579b01d5ecf3c48e85d57ffe152ae9
- Cited by
- 22
- References
- 58
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 4 · 2023: 1 · 2022: 3
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- BMC Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Intermountain Healthcare
- National Institutes of Health
- National Cancer Institute (R21CA256372, UH3CA227955, R21CA255312)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- colorectal cancer, KRAS mutation, MEK inhibitor resistance, Src kinase inhibition, dasatinib, consensus molecular subtypes, mesenchymal stem-like cells, epithelial-mesenchymal transition, cancer stem cells, RAS/MAPK pathway, gene expression signatures, Wnt signaling, drug repurposing, biomarker-guided therapy
- MeSH terms
- Antineoplastic Agents, Humans, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, src-Family Kinases, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Signaling System, Protein Kinase Inhibitors, Epithelial-Mesenchymal Transition, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy. https://app.cochat.ai/papers/10.1186/s12885-022-09344-3
- The paper
- Yang, M., Davis, T. B., Pflieger, L., Nebozhyn, M. V., Loboda, A., Wang, H., Schell, M. J., Thota, R., Pledger, W. J., & Yeatman, T. J. (2022). An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy. BMC Cancer. https://doi.org/10.1186/s12885-022-09344-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.